Reliant Medical Research

Miami, Florida 33165-3639

4 studies enrolling now · 15 studies all time

What they study most

Acute Coronary Syndrome, Alzheimer Disease, Atrial Fibrillation, COVID-19, Cutaneous Lupus Erythematosus (CLE), Diabetes Mellitus, Diabetic Foot Ulcer, Foot Ulcer, Hepatitis, Idiopathic Pulmonary Fibrosis, Parkinson's Disease, Idiopathic, Psychosis Associated With Alzheimer's Disease

Studies at this site

• A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis — Recruiting now
• Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) — Recruiting now
• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) — Recruiting now
• A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer — Recruiting now
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab — Running, not enrolling
• Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) — Stopped early
• Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome — Completed
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD — Completed
• A Study to Investigate Leramistat in Patients With IPF — Withdrawn before enrolling
• A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD — Completed
• Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis — Completed
• A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir — Completed
• A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) — Stopped early